» Articles » PMID: 34683901

Human Skin Permeation Enhancement Using PLGA Nanoparticles Is Mediated by Local PH Changes

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2021 Oct 23
PMID 34683901
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The steady improvement and optimization of transdermal permeation is a constant and challenging pharmaceutical task. In this study the influence of poly(lactide-co-glycolide) (PLGA) nanoparticles on the dermal permeation of the anti-inflammatory drug flufenamic acid (FFA) was investigated. For this aim, different vehicles under non-buffered and buffered conditions and different skin models (human heat separated epidermis and reconstructed human epidermis equivalents) were tested. Permeation experiments were performed using static Franz diffusion cells under infinite dosing conditions. Already the presence of drug-free nanoparticles increased drug permeation across the skin. Drug permeation was even enhanced when applying drug-loaded nanoparticles. In contrast, buffered vehicles with different pH values (pH 5.4-7.4) revealed the influence of the pH on the permeation of FFA. The change of the surrounding pH of the biodegradable nanoparticulate system was demonstrated and visualized using pH-sensitive fluorescent probes. While a potential contribution of hair follicles could be ruled out, our data suggest that the enhanced permeation of FFA through human skin in the presence of PLGA nanoparticles is mediated by a locally decreased pH during hydrolytic degradation of this polymer. This hypothesis is supported by the observation that skin permeation of the weak base caffeine was not affected.

Citing Articles

Electrical Impedance Spectroscopy Quantifies Skin Barrier Function in Organotypic In Vitro Epidermis Models.

van den Brink N, Pardow F, Meesters L, van Vlijmen-Willems I, Rodijk-Olthuis D, Niehues H bioRxiv. 2024; .

PMID: 38562885 PMC: 10983962. DOI: 10.1101/2024.03.18.585587.


Super-Antioxidant Vitamin A Derivatives with Improved Stability and Efficacy Using Skin-Permeable Chitosan Nanocapsules.

Oh H, Lee J, Kim S, Lee J, Shin Y, Choi W Antioxidants (Basel). 2023; 12(11).

PMID: 38001766 PMC: 10669859. DOI: 10.3390/antiox12111913.


The Contest of Nanoparticles: Searching for the Most Effective Topical Delivery of Corticosteroids.

Kalvodova A, Dvorakova K, Petrova E, Michniak-Kohn B, Zbytovska J Pharmaceutics. 2023; 15(2).

PMID: 36839836 PMC: 9962773. DOI: 10.3390/pharmaceutics15020513.


The Fundamental Role of Lipids in Polymeric Nanoparticles: Dermal Delivery and Anti-Inflammatory Activity of Cannabidiol.

Zamansky M, Zehavi N, Sintov A, Ben-Shabat S Molecules. 2023; 28(4).

PMID: 36838759 PMC: 9962451. DOI: 10.3390/molecules28041774.


, , and Evaluation of Nanoparticle-Based Topical Formulation Against Infection.

Sadozai S, Khan S, Baseer A, Ullah R, Zeb A, Schneider M Front Pharmacol. 2022; 13:909851.

PMID: 35873577 PMC: 9304580. DOI: 10.3389/fphar.2022.909851.


References
1.
Bronaugh R, Stewart R, Simon M . Methods for in vitro percutaneous absorption studies. VII: Use of excised human skin. J Pharm Sci. 1986; 75(11):1094-7. DOI: 10.1002/jps.2600751115. View

2.
Luengo J, Weiss B, Schneider M, Ehlers A, Stracke F, Konig K . Influence of nanoencapsulation on human skin transport of flufenamic acid. Skin Pharmacol Physiol. 2006; 19(4):190-7. DOI: 10.1159/000093114. View

3.
Perzov N, Padler-Karavani V, Nelson H, Nelson N . Characterization of yeast V-ATPase mutants lacking Vph1p or Stv1p and the effect on endocytosis. J Exp Biol. 2002; 205(Pt 9):1209-19. DOI: 10.1242/jeb.205.9.1209. View

4.
Santander-Ortega M, Stauner T, Loretz B, Ortega-Vinuesa J, Bastos-Gonzalez D, Wenz G . Nanoparticles made from novel starch derivatives for transdermal drug delivery. J Control Release. 2009; 141(1):85-92. DOI: 10.1016/j.jconrel.2009.08.012. View

5.
Schmook F, Meingassner J, Billich A . Comparison of human skin or epidermis models with human and animal skin in in-vitro percutaneous absorption. Int J Pharm. 2001; 215(1-2):51-6. DOI: 10.1016/s0378-5173(00)00665-7. View